Pipeline Overview

Asset
Indication
Preclinical
Phase I
Phase IIa
Phase IIb
Phase III
Milestone
AP1189
Rheumatoid Arthritis
1st-line in combination with MTX
SynAct-CS007:
Topline data,
H2 – 2023
DMARD-ID
Initiation,
H2 - 2022

Top-line data,
part A,
H2 - 2023
Nephrotic syndrome (iMN)
SynAct-CS003:
Key results,
H2 – 2023
Virus- Induced Respiratory Insufficiency
Data from viral
disease models,
H2 - 2022
Next indication
Next Gen NCEs
Inflammatory diseases
= Planned initiation in 2022